Quantum-Si to Present at the B. Riley Securities’ Disruptive Biotech Enabling Technologies Virtual Mini Conference

GUILFORD, Conn.–(BUSINESS WIRE)– Mar. 28, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced that it will be participating in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference.

Quantum-Si’s management is scheduled to present virtually on Thursday, April 7, 2022 at 10:20 am ET. To listen to the live event, please contact your B. Riley Securities representative with interest.

About Quantum-Si Incorporated
Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantumsi.supremeclients.com.

View source version on businesswire.comhttps://www.businesswire.com/news/home/20220328005817/en/

Investor Contacts
Juan Avendano
Mike Cavanaugh
[email protected]

Jon Yu
[email protected]

Source: Quantum-Si Incorporated